Niu et al. showed that combining a novel anti-TGF-β/VEGF bispecific antibody Y332D with PD-1 blockade increased the density and function of tumour-infiltrating lymphocytes, showing a stronger anti-tumour effect [40]. This evidence concerns the gene TGFB1 and neoplasm.